New Product Marketing Authorizations (MAs) in the pharmaceutical industry are official approvals granted by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other national authorities, that allow a company to market a new medicinal product. These authorizations are granted after a rigorous evaluation of the drug’s safety, efficacy, and quality based on extensive preclinical and clinical trial data, as well as manufacturing standards and risk-benefit assessments. https://www.ddregpharma.com/regulatory/new-product-authorizations